Kairos Pharma, Ltd.
KAPA · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.19 | -0.21 | 0.62 | -0.19 |
| FCF Yield | -22.91% | 0.30% | -1.33% | -1.23% |
| EV / EBITDA | -6.82 | -17.72 | -62.09 | -17.89 |
| Quality | ||||
| ROIC | -49.06% | 119.36% | 96.29% | 246.89% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.52 | -0.04 | 0.34 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -4,982.72% | 122.95% | 14.32% | -969.16% |
| Safety | ||||
| Net Debt / EBITDA | 0.54 | -0.35 | -0.35 | -0.16 |
| Interest Coverage | -2.73 | -17.49 | -1.19 | -9.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,263.00 | -5,477.28 | -3,716.16 | -5,765.51 |